Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (431-440 of 477) with videos related to

Pageof 48
Sort By:
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validityPeter Tugwell, Maarten Boers, Maria-Antonietta D'Agostino, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012Daniel E Furst, Edward Clark Keystone, Alexander K So, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Pageof 48

Showing results (431-440 of 477) with videos related to

Sort By:
Pageof 48
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Seminars in Arthritis and Rheumatism|November 2, 2023
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working GroupDorthe B Berthelsen, Lee S Simon, John P A Ioannidis, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validityPeter Tugwell, Maarten Boers, Maria-Antonietta D'Agostino, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012Daniel E Furst, Edward Clark Keystone, Alexander K So, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
The Journal of Rheumatology|April 3, 2014
Updating the OMERACT filter: discrimination and feasibilityGeorge Wells, Dorcas E Beaton, Peter Tugwell, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Pageof 48